Roivant Sciences Transfers Psoriasis Drug Development to Organon
Roivant Sciences’ Strategic Move
Roivant Sciences has made a significant decision by offloading its psoriasis medicine developer, Dermavant Sciences. This acquisition by Organon is valued at up to $1.2 billion and aims to boost health care innovation in dermatological treatments.
Insights on the Acquisition
Dermavant Sciences is notably recognized for creating immuno-dermatology treatments, with the FDA-approved Vtama cream making a substantial impact in treating plaque psoriasis. This deal exemplifies Organon's commitment to expanding its offerings in the health care landscape.
- Value of Acquisition: Up to $1.2 billion
- Key Product: Vtama cream
- Focus: Immuno-dermatology treatments
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.